Rexlemestrocel-L's dual BLA strategy in HFrEF and CLBP tests whether MSC therapy can achieve broad registrational success across two large, mechanistically distinct indications

Bull

A statistically significant reduction in pain scores at 12 months versus sham control would confirm that rexlemestrocel-L's anti-inflammatory and regenerative mechanism translates to functional benefit in degenerative disc disease, validating the cross-indication thesis. This outcome would trigger the Q3 2027 BLA submission with RMAT priority review eligibility, potentially positioning rexlemestrocel-L as the first disease-modifying cell therapy approved in CLBP — a multi-billion dollar market with no approved regenerative option. Combined with a successful HFrEF approval, it would establish MSC therapy as a platform across mechanistically distinct indications.

Bear

The most likely failure mode is insufficient separation from sham control at 12 months, a historically difficult bar in chronic pain trials where placebo response rates are high and patient-reported pain endpoints are susceptible to expectation bias. A second risk is heterogeneity in the disc pathology population diluting the treatment signal, particularly if patients with more advanced degeneration respond poorly; the 300-patient trial may also be underpowered to demonstrate robust effect sizes required for full approval. A negative or inconclusive readout would eliminate the CLBP BLA, reduce the dual-indication thesis to a single cardiac program, and raise questions about MSC platform generalizability.